Planned safety analysis of a breast cancer prevention study reveals encouraging news for Exemestane

Dec 14, 2008

An interim analysis of a breast cancer prevention study using exemestane (Aromasin®) finds an "acceptable" level of bone loss.

The ongoing phase II study details reported today, by Jennifer Eng-Wong, MD, a breast cancer specialist at Georgetown's Lombardi Comprehensive Cancer Center at the San Antonio Breast Cancer Symposium, examines the use of exemestane in postmenopausal women who are at an increased risk of developing breast cancer based on commonly used risk assessment measures. In addition to exemestane, all the study participants received calcium carbonate and vitamin D.

Wong's report represents findings from a planned interim safety analysis in 18 women who completed one year of exemestane.

"We found a drop in bone mineral density in these women similar to what we've seen in women taking exemestane in the adjuvant treatment setting." Eng-Wong reports. "Like aromatase inhibitors in the adjuvant setting there is a small amount of bone loss in the spine and hip. The long term clinical impact of the small decrease is not known."

The exemestane study continues with endpoints including bone density measurements and change in breast density over two years of treatment. Dense breasts as observed on a mammogram are associated with an increase in a woman's risk of developing breast cancer.

Source: Georgetown University

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

Hormone-blocking drug reduces breast cancer risk

Jun 04, 2011

(AP) -- Millions of women at higher-than-usual risk of breast cancer have a new option for preventing the disease. Pfizer Inc.'s Aromasin cut the risk of developing breast cancer by more than half, without the side effects ...

The future of breast cancer prevention

Mar 31, 2011

Drugs could be used to prevent breast cancer in women at high risk of the disease in the same way that statins are used for heart disease if trials looking at ways of predicting risk are successful, according to an international ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

18 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
1 / 5 (1) Dec 14, 2008
CYROABLATION WORKS, and it has no side effects!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.